Investors


Investor Relations


Interim Summary

TurnoverQ2 2021

40 (41)

MSEK

EBITDAQ2 2021

-14 (-0)

MSEK

Jens Lindberg
Vice President Commercial Operations

CEO Comments

At the end of July, an important milestone was reached with the gratifying news that we received – earlier than expected – DCP approval for the pharmaceutical product Sedaconda (isoflurane), as well as the treatment inhaled sedation. As a result, we are now seeking national approvals to launch the inhaled sedation therapy in 15 European countries. These national processes are expected to take about 1-3 months. Further encouraging news was announced on 13 August when Sedaconda1 received its first national approval, from the French medicines agency ANSM.

Sales in the quarter totalled SEK 40 million, an increase of about 3 percent at fixed exchange rates compared to last year. The gross margin for the quarter was 66 percent, up 2 percentage points year-on-year as a result of lower transport costs in the quarter as a greater proportion of freight was carried by sea rather than by air.

In Germany, our largest market, we saw continued strong momentum with sales up year-on-year and almost in line with Q1, despite a sharp downturn in the number of Covid-19 intensive care patients in May-June. This is a positive sign that clinics are continuing to broaden use beyond Covid-19 patients.

Other direct sales in Europe decreased compared to last year as a result of the slowing third wave of the pandemic. The previous year was notable for a massive increase in sales during April-May, at the start of the pandemic. These countries, which have a substantially smaller customer base than Germany, are even more affected in terms of sales by the decreasing number of Covid-19 patients in the ICU. However, we are seeing continued momentum here too, with existing and new hospital customers beginning to broaden use to other patient groups. These relationships will be very valuable for future marketing authorisations.

Sedana Medical operates according to a clear strategy based on several steps to develop inhaled sedation into a global standard therapy in intensive care.

The first step in the strategy is to establish AnaConDa (to be renamed Sedaconda ACD) in selected markets. During the quarter, we continued to strengthen our presence in our distributor markets, particularly in Latin America. Sales increased sharply compared to the previous year, and Mexico is our second largest market in the second quarter. Latin America is one of the regions in the world where the pandemic has put the greatest strain on health systems, with acute shortages of propofol in many countries. Our success can also be largely attributed to our local distributor, one of Latin America’s leading distributors of healthcare products. There is strong interest in launching and selling AnaConDa/Sedaconda ACD in the markets we do not cover ourselves, which gives us the opportunity to work with the best distributors in each country.

With regard to the second step in our strategy, having the pharmaceutical product Sedaconda and inhaled sedation therapy approved, it was very pleasing to obtain DCP approval in July, as well as the first national marketing authorisation in France in August. Now that we are approaching commercialisation in Europe, our work has been concentrated on pre-launch activities. We are focusing on the pricing, procurement and reimbursement processes in each country, which is sometimes resource-intensive work, but acceptance by purchasers in healthcare systems is a key factor for successful commercialisation. In addition, despite continued shutdowns in many of our markets, we have managed to step up our level of activity at local congresses and meetings. We have also organised our own well-attended symposia in conjunction with these congresses. All in all, our level of activity has increased and will increase further as we come closer to the start of sales.

Part of the work ahead of the launch is the change of name for our medical device AnaConDa to Sedaconda ACD, which stands for Anaesthetic Conserving Device. The name strengthens the link to Sedana Medical and the unique area of use of sedation. The pharmaceutical product Sedaconda (isoflurane) is to be administered via AnaConDa/Sedaconda ACD, together making up the inhaled sedation therapy. The name change will be launched on 1 October.

Preparations ahead of our American registration were intense during the quarter. Shortly after the end of the quarter, we were able to announce that we had held an End of Phase II meeting with the US Food and Drug Administration (FDA). The purpose of this advisory meeting was to discuss the documentation ahead of phase 3 and to agree on the plan and design of the phase 3 studies. The meeting was successful – the FDA accepted our proposed phase 3 programme, including the study design and the primary endpoint for the studies – and means that we are able to enter phase 3 in line with the previously communicated timetable.

We are now working to submit an Investigational New Drug (IND) application in the autumn to allow us to start clinical studies and enrol the first patients in the studies at the turn of Q1/Q2 2022. There has been significant interest in participating in the studies from a large number of leading US centres. We aim to include around 30 centres and look forward to starting the inclusion of patients. We have established a subsidiary and recruited employees in the United States who will be involved in the studies. By successfully carrying out two randomised controlled trials, each including around 250 patients, we plan to obtain marketing authorisation before the end of 2024.

With regard to the third step in our strategy; With the aid of more studies, securing medical evidence showing that inhaled sedation is a better and more cost-effective treatment than today’s intravenous standard therapy, it was very pleasing to be able to report during the quarter that the Sedaconda study (SED001) was named one of the three best posters at the 52nd DGIIN & ÖGIAIN intensive care conference from 16 to 18 June 2021. DGIIN & ÖGIAIN is the joint annual congress of the German and Austrian acute and intensive care associations. It is highly positive that the study is receiving attention in Germany, which is our largest market.

All in all, we look back on yet another intensive quarter with success in all the steps in our strategy. On 1 October, I will be handing over the baton to our incoming President and CEO Johannes Doll and will continue in my role as Commercial Director. We look forward to coming back to you.

Jens Lindberg, Vice President Commercial Operations

 Read the report in its entirety here.

Calendar
Dates for upcoming information

Date Event
4 November, 2021 Q3 interim report 2021

Annual & Interim Reports

2016
Annual Reports Interim Reports
2016  Sedana Medical AB (publ)
Annual Report 2016 (in Swedish)
N/A N/A

Click on the + sign to expand reports on desired year, then click on a report to open it.
You need a pdf reader to view the files.

Content

Annual General Meeting 2021

Downloadable files:

Annual General Meeting 2020

Downloadable files:

Annual General Meeting 2019

Downloadable files:

Annual General Meeting 2018

Downloadable files:

  Notice of Annual General Meeting 2018
  Nomination Committee’s proposal
  Power of Attorney form
  Minutes from the Annual General Meeting 2018


Corporate Governance

Corporate governance includes information about our Board of Directors, the management team, guidelines for remuneration to the senior management, our auditors, general meetings and our articles of association.

Board of Directors

The registered office of the company is situated in the municipality of Danderyd. The Board of Directors shall consist of not less than three (3) and not more than six (6) members.

Thomas Eklund Chairman
of the Board
  • Born: 1967
  • Nationality: Swedish
  • Position: Board member and Chairman of Sedana Medical since 2014.
  • Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.
  • Other current engagements: Board member in Biotage AB, Bio-Works Technologies AB, Bio-Works Sweden AB, Boule Diagnostics AB, Excillum Aktiebolag, Immedica Pharma Holding AB, Mabtech Group Holding AB, Mabtech Holding AB, Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,666,464 shares via Tedsalus AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Claus BjerreMember &
vice chairman
of the Board
  • Born: 1971
  • Nationality: Danish
  • Position: Member and vice chairman of Sedana Medical since 2021.
  • Education and professional experience: Claus holds an M.Sc. from the Copenhagen Business School and an MBA in Strategy and Finance from the UCLA Anderson School of Management. He served as CEO of Atos Medical from early 2014 through 2018. Atos Medical was sold by EQT to PAI Partners during his tenure in 2016. From 2006 to 2014, Claus held numerous senior leadership positions with Coloplast A/S, a Danish global consumable medtech company, most recently as President, North America, Japan, and Australia. Before joining Coloplast, Claus spent 10 years within corporate strategy, mergers and acquisitions, and private equity across industries working for McKinsey & Company, Nordic Capital, and Mattel.
  • Other current engagements: Claus is currently ordinary member of the board of directors and vice chairman of the board of Ellab, owned by EQT, and senior advisor at KKR & Co, Inc.
  • Shareholding in Sedana Medical: 0 shares.
    Independent of major shareholders, not independent of the Company and the Executive Management.
Bengt Julander Member
of the Board
  • Born: 1953
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2011.
  • Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Chairman in Linc AB, with investments in the pharmaceutical and medtech industry.
  • Other current engagements: Chairman in Linc AB and Knil AB. Board member in Animal Probiotics Sweden AB, Cronhamn Invest AB, Livland Skog AB, Medivir Aktiebolag, nWise AB, Part Production Sweden AB, Reison Medical AB, Stille AB and Swevet Holding AB. Board member and deputy board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 7,598,804 shares via Linc AB.
    Independent in relation to the Company and its management but not in relation to major shareholders.
Ola Magnusson
Member
of the Board
  • Born: 1948
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2005. Formerly CEO of Sedana Medical (2005 – 2011).
  • Education and professional experience: Ola hold an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry mainly within marketing, sales and different management positions including 4 years in the US for Pharmacia in the 80ies and 90ies. Ola also has more than 20 years experience in the medical device industry as CEO for Louis Gibeck AB where he was responsible for the listing on the OTC exchange in Stockholm and as Managing Director EMEA, Hudson RCI AB after its acquisition of Louis Gibeck AB. Ola was the founder of Sedana Medical 2005 and acted as CEO up to 2011.
  • Other current engagements: Chairman in Eataway AB. Board member in TransCutan AB and board member in smaller family companies.
  • Shareholding in Sedana Medical: 4,544,288 shares via Magiola Consulting AB and 39,440 privately.
    Independent in relation to the Company and its management and in relation to major shareholders.
Eva Walde Member
of the Board
  • Born: 1963
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2018.
  • Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.
  • Other current engagements: Vice President Marketing Director at Olink Proteomics AB, board member at Senzime AB, CEO and Chairman of the board in the own company Movits Consulting AB and deputy board member in Finnson & Partners AB.
  • Shareholding in Sedana Medical: 12,800 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Christoffer Rosenblad Member
of the Board
  • Born: 1975
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2020.
  • Education and professional experience: Christoffer has a Master of Science degree from Chalmers University of Technology and a degree in economics from the School of Business and Economics at the University of Gothenburg. During 2012-2020 he was CFO for XVIVO Perfusion AB. During the years 2015–2017, he led XVIVO’s North American operations and resided in the United States. From 2001 to 2012, he has had leading positions in finance and strategic management at Novartis and LG Electronics.
  • Other current engagements: COO (since 2020) and Vice President (since 2017) at XVIVO Perfusion AB.
  • Shareholding in Sedana Medical: no shares.
    Independent in relation to the Company and its management and in relation to major shareholders.

Management team

Johannes Doll
President and CEO
  • Born: 1981
  • Nationality: German
  • Position: President and CEO since October 1st, 2021.
  • Johannes hold an MBA, from the University of Texas, and Dipl. Kaufmann, WHU Otto Beisheim School of Management, Germany. From 2013-2021, Johannes was part of the Executive Management team at Orexo AB, most recently as Executive Vice President and Chief Commercial Officer. Prior to joining Orexo, Johannes worked at McKinsey & Company from 2004 to 2013, advising international clients in the pharmaceutical and medical devices industry and the private equity sector.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Susanne Andersson
CFO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Financial Officer since January 2021.
  • Education and professional experience: Bachelor of Business Administration from College of Charleston, S.C. USA. CFO at Pricer, CFO & Head of Communications at ChromoGenics, VP Head of Investor Relations at PostNord, CFO at Nordic Mines and 15+ years of international experience of various finance and management roles within Ericsson and the telecom industry.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Sylvia Buddenbaum Eriksson
HR director
  • Born: 1968
  • Nationality: Swedish
  • Position: HR director, Consultant since August 2020.
  • Education and professional experience: B.Sc. Business and Economics, Stockholm University. Consultant own business since February 2019. Previously i.a. HR director GroupM, HR director Lidl Sweden, HR & Communication Apoteksgruppen AB/Apoteket omstrukturering AB, HR director Unilever Nordic and different roles within finance.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares, Related parties 72 shares.
Robert vom Dorp
Vice President Business Development
  • Born: 1970
  • Nationality: German
  • Position: Vice President Business Development since April 2020, employed
    since 2005.
  • Education and professional experience: Robert holds an MBA in economics from the University of Applied Sciences at Hochschule Koblenz. Has also studied industrial organisation. Experience in sales in the medtech industry since 2001 as account manager within anaesthesia, ventilation and intensive care at Hudson RCI and Teleflex Medical. Sales manager at Sedana Medical with responsibilities for marketing, sales, strategy and operations in Germany, Austria and Switzerland.
  • Other current engagements:
  • Shareholding in Sedana Medical: 305,000 shares.
Peter Fröberg
Chief Technology Officer
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Technology Officer, Consultant since November 2020.
  • Education and professional experience: MSc from the Royal Institute of Technology in Stockholm. More than 20 years’ experience of product and business development, as product manager at Elekta Instrument AB and as a consultant within Life Science.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Stefan Krisch
Supply Chain & Manufacturing Director
  • Born: 1974
  • Nationality: Swedish
  • Position: Supply Chain and Manufacturing Director since March 2021.
  • Education and professional experience: : Stefan holds a Master of Science degree in Mechanical Engineering from KTH Stockholm, Sweden, and TUD Darmstadt, Germany. In addition he studied business administration and management at Stockholm Business School, Stockholm University. Stefan has some 20 years of experience in leading positions in various industries. Mainly within manufacturing, logistics, and business development. Previously CEO of Svensk Dos AB, CEO of Dipylon Medical AB and Production Manager at AB Gustavsberg. Founder of Eker Bicycles AB and Eker Production Ltd., Uganda.
  • Other current engagements: Chairman of the Board Eker Bicycles AB and Eker Production Ltd., Uganda. Owner K-Consulting (sole proprietor).
  • Shareholding in Sedana Medical: 5,600 shares, 25,200 warrants.
Jens Lindberg
Vice President Commercial Operations
  • Born: 1971
  • Nationality: Swedish
  • Position: Vice President Commercial Operations since April 2020.
  • Education and professional experience: B.S. Business Administration & 25 years of experience from local & global commercial roles in AstraZeneca.
  • Other current engagements:
  • Shareholding in Sedana Medical: 0 shares. 12,000 warrants in program 2020/2023
    representing 12,000 shares.
Peter Sackey
CMO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Medical Officer of Sedana Medical since January 2018, employed since 2018.
  • Education and professional experience: Peter received his doctor´s degree from Karolinska Institutet in 1997. He has worked for twenty years at the Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital and is Board-certified in Anesthesiology (DESA) and Intensive Care (EDIC). He completed his PhD thesis entitled “Isoflurane sedation in Intensive Care Unit patients” at Karolinska Institutet in 2006. He is an Associate professor at Karolinska Institutet, has supervised several PhD students and has active ICU-related research.
  • Previous positions: Senior Consultant, Head of Neurocritical Care, Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital in Stockholm.
  • Other current engagements: Associate professor, Department of Physiology and Pharmacology, Karolinska Institutet.
  • Shareholding in Sedana Medical: 187,468 shares and 105,172 warrants in program 2019/2022 representing 105,172 shares.
Jessica Westfal
Vice President Regulatory Affairs & QA
  • Born: 1974
  • Nationality: Swedish
  • Position: Vice President Regulatory Affairs and QA since May 2020, employed since 2020.
  • Education and professional experience: Jessica holds a MSc in Analytical Chemistry at
    Umeå University. She is a former employee at Unimedic AB (between 2006-2020) as Head of Quality and Product Development, and before that at AstraZeneca (between 1998-2006).
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares. 4,000 warrants in program 2020/2023
    representing 4,000 shares.

Guidelines for remuneration to senior management

The main principle is that remuneration and other employment conditions for members of senior manage¬ment shall be based on market terms and be competitive in order to ensure that the group can attract and retain competent senior managers at a reasonable cost for the company.

The total remuneration for senior management shall consist of fixed salary, variable remuneration, pension and other benefits.

The Board fee is decided by the Annual General Meeting. In so far as board members elected by the Annual General Meeting are performing work that stretches beyond the tasks of the Board of Directors, it shall be possible to pay them for such work. Such remuneration shall be market-based and shall be approved by the Board of Directors.

The remuneration to the Board of Sedana Medical is determined at the Annual General Meeting following proposals from the Nomination Committee.

Audit Committee

During 2020 an audit committee was established. On behalf of the Board, the Audit Committee monitors and reviews the following:

  • The scope and correctness of the financial statements
  • Compliance with legal and regulatory requirements
  • Internal control over financial reporting
  • Risk management
  • The Annual Report and interim reports
  • Audits and audit fees

Members of the Audit Committee
The Audit Committee consists of three Board members as appointed by the Board. The current members are:
Christoffer Rosenblad (Chairman of the Committee)
Thomas Eklund
Bengt Julander

Auditor

Öhrlings PricewaterhouseCoopers AB was elected as auditors at the Annual General Meeting in May 2021 for the period leading up to the Annual General Meeting 2022. The principal responsible is authorized public accountant Leonard Daun.

Fees for auditing in Sedana Medical are determined at the AGM following proposals from the Nomination Committee.

General Meeting

The General Meeting of shareholders is the highest decision-making entity in Sedana Medical AB. At the General Meeting, all shareholders are invited to exercise their rights according to their respective shareholdings.

Shareholders wishing to participate in General Meetings must be listed as a shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

ARTICLES OF ASSOCIATION OF SEDANA MEDICAL AB (PUBL)

Reg. no. 556670-2519

Adopted at the annual general meeting held on 10 May 2021

§ 1 Name of the company
The name of the company is Sedana Medical AB (publ).

§ 2 Registered office of the board of directors
The registered office of the company shall be situated in the municipality of Danderyd.

§ 3 Object of the company’s activities
The object of the company’s activities is to develop, manufacture and market pharmaceuticals and medical- technical products,
and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 800,000 and not more than SEK 3,200,000.

§ 5 Number of shares
The number of shares shall be not less than 32,000,000 and not more than 128,000,000.

§ 6 Board of Directors
The board of directors shall consist of not less than three (3) and not more than six (6) members. The members are to be elected annually at the annual general meeting until the end of the next annual general meeting.

§ 7 Auditors
The company shall have a minimum of one (1) and a maximum of two (2) auditors, with a maximum of two (2) deputy auditors. A registered accounting firm may also be appointed as auditor.

§ 8 Place of General Meetings
Any general meeting in the Company shall be held in Danderyd or Stockholm.

§ 9 Notice of General Meeting
Notices of general meetings shall be made by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. At the same time as notice is given it shall be announced in Dagens industri that a notice has been made.

Shareholders wishing to participate at a general meeting shall notify the company no later than the date specified in the notice of the general meeting. Such date may not be a Sunday, other public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday before the general meeting. A shareholder may be accompanied by advisors at a general meeting only if he or she notifies the company of the number of advisors in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

§ 10 Annual General Meeting
The following matters shall be addressed at the annual general meeting:
1. Election of chairman of the meeting

2. Preparation and approval of the voting register

3. Election of one or two persons to attest the minutes

4. Determination of whether the meeting has been duly convened

5. Approval of the agenda

6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated financial statements and the auditor’s report on the group

7. Resolutions regarding:

(a) adoption of the balance sheet and income statement and, where applicable, the consolidated balance sheet and the consolidated income statement

(b) allocation of the company’s profit or loss according to the adopted balance sheet

(c) discharge from liability for board members and the managing director

8. Determination of fees to be paid to the board of directors and the auditors

9. Determination of the number of board members and, where applicable, deputy members, and the number of auditors and, where applicable, deputy auditors

10. Election of the board of directors and auditors

11. Any other business incumbent on the meeting according to the Swedish Companies Act or the articles of association

§ 11 Financial year
The company’s financial year shall be 1 January – 31 December.

§ 12 CSD clause
The shares of the company shall be registered in a CSD register in accordance with the Central Securities Depositaries and Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

 Click here to download the Articles of Association.

Ownership

Below is Sedana Medical’s ownership structure.

NameNum. of sharesCapitalVotesVerified       
Handelsbanken Funds 8,580,052 9.31% 9.31% 2021-09-30
Swedbank Robur Funds 8,314,933 9.02% 9.02% 2021-09-30
Linc AB (Bengt Julander) 7,598,804 8.24% 8.24% 2021-09-30
Anders Walldov 7,200,000 7.81% 7.81% 2021-09-30
Ola Magnusson 4,583,728 4.97% 4.97% 2021-09-20
Sten Gibeck 4,279,776 4.64% 4.64% 2021-09-30
Öhman Funds 3,898,485 4.23% 4.23% 2021-09-30
Third Swedish National Pension Fund 2,000,000 2.17% 2.17% 2021-09-30
Avanza Pension 1,978,681 2.15% 2.15% 2021-09-30
Berenberg Funds 1,919,532 2.08% 2.08% 2021-03-31
Total 1050,353,99154.62%54.62%
Others41,832,96945.38%45.38%
Total number of owners 7,633 2021-09-30
Total number of shares 92,186,960 2021-09-30

Source: Modular Finance

Warrant programmes

Sedana Medical has outstanding warrant programmes with a total maximum dilution of 547 272 shares.
Warrant program 2019/2022, total maximum dilution of 356 340 shares,
exercisable 1 July to 30 November 2022 at a strike price of 35,60 SEK per share.
Warrant program 2020/2023, total maximum dilution of 42 480 shares,
exercisable 1 July to 30 November 2023 at a subscription price of SEK 83,70 per share.
Warrant program 2020/2024, total maximum dilution of 148 452 shares,
exercisable 1 February to 31 May 2024 at a subscription price of SEK 123,90 per share.

Presentations

Date Description Material
Aug 19, 2021 Sedana Medical – webcast Q2 2021 report.
To participate, please dial: +46 8 505 583 52
For additional log in information:
https://financialhearings.com/event/13794
 More info
May 6, 2021 Sedana Medical – webcast Q1 2021 report.  More info
Feb 25, 2021 Sedana Medical – webcast Q4 2020 report.  More info
Nov 26, 2020 Sedana attending Redeye Life Science Day 2020.  Play Video
Nov 17-19, 2020 Sedana attending 11th Annual Jefferies Global Healthcare Conference.  More info
Nov 5, 2020 – 14:00 Sedana Medical – webcast Q3 2020 report.  More info
Sep 9, 2020 Sedana attending Carnegie Virtual Nordic Small Mid Cap Seminar.  View Program
Sep 2-3, 2020 Sedana attending Pareto Securities’ 11th Annual Healthcare Conference.  More info
Sep 1, 2020 Sedana attending Danske Bank Small & Mid Cap Seminar.  Play Video
Jul 10, 2020 Presentation of the positive top line result in the pivotal IsoConDa study.  Play Live Stream
May 19, 2020 CEO presentation in connection with AGM 2020-05-19.  Play Video
May 7, 2020 Presentation of the interim report for the first quarter 2020.  Play Video
Apr 8, 2020 Sedana Medical’s CEO on prioritizing in the Corona crisis.  Play Video
Nov 27, 2019 VATOR SECURITIES UNICORN SUMMIT 2019.  Play Video
Sep, 2019 Sedana Medical – Management Presentation September 2019.  View Presentation
Jun 10, 2019 Redeye Growth Day 2019.  Play Video
May 8, 2019 Presentation of the interim report for the first quarter 2019.  Play Video
Mar 14, 2019 Stockholm Corporate Finance Life Science Seminar.  Play Video
Mar 8, 2019 IsoConDa phase III pivotal study, interim analysis report, 8 March 10:30.  Play Video
Sep 6, 2018 Pareto Securities’ 9th Health Care seminar in Stockholm.  Play Video
Apr 27, 2018 Event at ProHearings (English).  Play Video
Mar 7, 2018 Sitdown at Erik Penser 2018 (Swedish).  Play Video
Mar 6, 2018 Stockholm Corporate Finance Life Science Seminar (Swedish).  Play Video
Nov 24, 2017 Redeye seminar (Swedish).  Play Video
Jun 29, 2017 Trading Direkt Interview with CEO Christer Ahlberg (Swedish).  Play Video

Shares

Stock Graph

Share
ISIN-code
Share
Shortname
Current
Share Price
SE0015988373 SEDANA  Click here!
The LEI code is: 549300FQ3NJRI56LCX32
Certified Adviser: Erik Penser Bank – Tel: +46 (0)8-463 80 00 – Apelbergsgatan 27, Box 7405, 103 91 Stockholm, Sweden
Analyst(s) covering Sedana Medical: Peter Östling, Pareto Securities and Carl Mellerby, SEB

IPO

 Sedana Medical Investor Relation

 

Address:
Sedana Medical AB (publ)
Vendevägen 89
SE-182 32 Danderyd
Sweden
Phone: +46 (0)8-124 05 200
Investor relation: ir@sedanamedical.com